



HAL
open science

Chalcone JAI-51 improves efficacy of synchrotron microbeam radiation therapy of brain tumors.

Audrey Bouchet, Ahcene Boumendjel, Enam Khalil, Raphael Serduc, Elke Bräuer, Erik Albert Siegbahn, Jean A. Laissue, Jean Boutonnat

► **To cite this version:**

Audrey Bouchet, Ahcene Boumendjel, Enam Khalil, Raphael Serduc, Elke Bräuer, et al.. Chalcone JAI-51 improves efficacy of synchrotron microbeam radiation therapy of brain tumors.. *Journal of Synchrotron Radiation*, 2012, 19 (Pt 4), pp.478-82. 10.1107/S0909049512015105 . inserm-00856984

HAL Id: inserm-00856984

<https://inserm.hal.science/inserm-00856984>

Submitted on 2 Sep 2013

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Chalcone JAI-51 improves efficacy of synchrotron microbeam radiation therapy of brain tumors


Audrey Bouchet, Ahcene Boumendjel, Enam Khalil, Raphael Serduc, Elke Bräuer, Erik Albert Siegbahn, Jean A. Laissue and Jean Boutonnat

J. Synchrotron Rad. (2012). **19**, 478–482

Copyright © International Union of Crystallography

Author(s) of this paper may load this reprint on their own web site or institutional repository provided that this cover page is retained. Reproduction of this article or its storage in electronic databases other than as specified above is not permitted without prior permission in writing from the IUCr.

For further information see <http://journals.iucr.org/services/authorrights.html>



Synchrotron radiation research is rapidly expanding with many new sources of radiation being created globally. Synchrotron radiation plays a leading role in pure science and in emerging technologies. The *Journal of Synchrotron Radiation* provides comprehensive coverage of the entire field of synchrotron radiation research including instrumentation, theory, computing and scientific applications in areas such as biology, nanoscience and materials science. Rapid publication ensures an up-to-date information resource for scientists and engineers in the field.

Crystallography Journals **Online** is available from journals.iucr.org

Chalcone JAI-51 improves efficacy of synchrotron microbeam radiation therapy of brain tumors

Audrey Bouchet,^{a,b,c} Ahcene Boumendjel,^d Enam Khalil,^e Raphael Serduc,^{a,b,*} Elke Bräuer,^c Erik Albert Siegbahn,^f Jean A. Laissue^g and Jean Boutonnat^h

^aINSERM, U836, F-38043 Grenoble, France, ^bGrenoble Institut des Neurosciences, Université Joseph Fourier, UMR-S836, F-38043 Grenoble, France, ^cEuropean Synchrotron Radiation Facility, F38043 Grenoble, France, ^dCNRS, UMR 5063, Bâtiment E, Pôle Chimie, F-38700 Grenoble, France, ^eFaculty of Pharmacy, University of Jordan, Amman, Jordan, ^fDepartment of Physics P8:02, Stockholm University, S-17176 Stockholm, Sweden, ^gInstitute of Pathology, University of Bern, CH-3010 Bern, Switzerland, and ^hDépartement d'Anatomie et Cytologie Pathologiques (DACP), UJF, UMR_S1036 BCI, CHU, Hôpital Michallon, Grenoble, F-38000, France.
E-mail: raph.serduc@gmail.com

Microbeam radiation therapy (MRT), a preclinical form of radiosurgery, uses spatially fractionated micrometre-wide synchrotron-generated X-ray beams. As MRT alone is predominantly palliative for animal tumors, the effects of the combination of MRT and a newly synthesized chemotherapeutic agent JAI-51 on 9L gliosarcomas have been evaluated. Fourteen days (D14) after implantation (D0), intracerebral 9LGS-bearing rats received either MRT, JAI-51 or both treatments. JAI-51, alone or immediately after MRT, was administered three times per week. Animals were kept up to ~20 weeks after irradiation or sacrificed at D16 or D28 after treatment for cell cycle analysis. MRT plus JAI-51 increased significantly the lifespan compared with MRT alone ($p = 0.0367$). JAI-51 treatment alone had no effect on rat survival. MRT alone or associated with JAI-51 induced a cell cycle blockade in G2/M ($p < 0.01$) while the combined treatment also reduced the proportion of G0/G1 cells. At D28 after irradiation, MRT and MRT/JAI-51 had a smaller cell blockade effect in the G2/M phase owing to a significant increase in tumor cell death rate ($<2c$) and a proportional increase of endoreplicative cells ($>8c$). The combination of MRT and JAI-51 increases the survival of 9LGS-bearing rats by inducing endoreduplication of DNA and tumor cell death; further, it slowed the onset of tumor growth resumption two weeks after treatment.

1. Introduction

Microbeam radiation therapy (MRT) is an alternative form of brain tumor radiosurgery which is being developed worldwide, to a large extent at the European Synchrotron Radiation Facility (France) (Slatkin *et al.*, 1992). It uses synchrotron-generated X-rays spatially fractionated into lattices of quasi-parallel microbeams (tens of micrometres wide, hundreds of micrometres spaced on-centre) (Slatkin *et al.*, 1994, 1995). Orthogonal crossfired irradiations performed on a 9L gliosarcoma (9LGS) model implanted in rat brains showed that MRT increases significantly the median survival times of irradiated animals without severely impairing unidirectionally irradiated ipsilateral or contralateral brain tissues (Serduc *et al.*, 2008; Smilowitz *et al.*, 2006; Dilmanian *et al.*, 2002; Laissue *et al.*, 1998). Tumor control might be related to a preferential effect of MRT on tumor vessels: first evidence has recently

been given *in vivo* (Bouchet *et al.*, 2010); recent experimental data showed a significant decrease in tumor blood volume after MRT, associated with an 80% tumor control rate (Bouchet *et al.*, 2010). However, despite the high radiation doses used (Serduc, Bouchet *et al.*, 2009; Serduc, Bräuer-Krisch *et al.*, 2009; Bouchet *et al.*, 2010), radio-resistant 9LGS (Kim *et al.*, 1999) was not totally sterilized and some tumor cells located at the tumor margins kept proliferating [Ki67 positive labelling (Bouchet *et al.*, 2010; Serduc, Bouchet *et al.*, 2009)].

Clinical brain tumor treatment is often based on chemotherapy and radiotherapy (Stupp *et al.*, 2005; Stupp & Roila, 2008). Chemotherapy, adjuvant to radiotherapy, contributes to tumor control by decreasing mitotic activity of and infiltration by surviving tumor cells (Bauman *et al.*, 1999), but the median overall lifespan of glioblastoma-bearing patients has only increased by 2.5 months in the course of the last 30 years.

Recent clinical trials have used bevacizumab and irinotecan on recurrent malignant glioma; toxicity was acceptable, but the treatment resulted in only 38% probability for six months progression-free survival (Vredenburgh, Desjardins, Herndon, Dowell *et al.*, 2007; Vredenburgh, Desjardins, Herndon, Marcello *et al.*, 2007). Currently, there is no other regimen for glioblastoma treatment than the Stupp protocol (Stupp *et al.*, 2005), which ends up with a low benefit in terms of overall survival. Some studies have described the anti-mitotic potential of flavonoid derivatives and their capacity to reverse multidrug resistance (Jeong *et al.*, 2007; Nakagawa-Goto *et al.*, 2010; Duraj *et al.*, 2005). Therefore, we have used a new chalcone (JAI-51) for the present study, a microtubule polymerization inhibitor that we have recently developed; JAI-51 has shown promising results on glioma models *in vitro* (Boumendjel *et al.*, 2008) and *in vivo* (rodents) (Boumendjel *et al.*, 2009). Chalcones that are flavone precursors have been investigated for their antiproliferative effect; flavonoids are polyphenols present in fruits, vegetables and many other comestibles. Colchicines, vinca alkaloids and taxanes are among many other natural substances that affect microtubular dynamics (Boumendjel *et al.*, 2008).

In this work we have evaluated for the first time the association of MRT with JAI-51 for the treatment of 9LGS implanted in rat brains, particularly the effects on the median survival time of those rats. Further, we have characterized the effect of both treatments, alone or combined, on the tumor cell cycle *ex vivo*.

2. Materials and methods

All operative procedures related to animal care strictly conformed to the guidelines of the French Government (licenses 380324/380456 and A3818510002); they were reviewed by the Internal Evaluation Committee for Animal Welfare of the ESRF. The anesthetic procedure used in this study was isoflurane (5% in air) for induction and an i.p. injection of xylazine/ketamine (64.5/5.4 mg kg⁻¹) for maintenance.

2.1. Tumor implantation

Ninety-four anesthetized male Fisher 344 rats were implanted with 10⁴ 9LGS cells in the right caudate nucleus as described elsewhere (Serduc, Bräuer-Krisch *et al.*, 2009). Animals bearing 9L gliosarcoma were randomly divided into four groups: untreated controls ['Control' (*n* = 26)], rats subjected to chemotherapy alone ['JAI-51' (*n* = 15)], rats given MRT 14 days after tumor implantation ['MRT' (*n* = 26)], rats with MRT plus chemotherapy ['MRT/JAI-51' (*n* = 27)]. Thirty-two rats were then culled at day 16 (D16) or D28 after treatment for cytometry studies (*n* = 32) and the others kept for survival analysis (*n* = 62).

2.2. Chemotherapy

The chalcone derivate JAI-51 was obtained by the condensation of 2',4',6'-trimethoxyacetophenone with 1-

methylindolyl-3-carboxaldehyde in the presence of KOH in a mixture of water and methanol. Freshly prepared aqueous JAI-51 solution (48 μL JAI-51 stock solution 2 M + 192 μL DMSO + 11.8 ml PBS) was administered to animals through i.p. injections (5.0 ml kg⁻¹ body weight) three times weekly with intervals of two days for four weeks. Chemotherapy (combined or not with radiation treatment) started 14 days after implantation, *i.e.* at the same day as MRT (D0).

2.3. Microbeam radiation therapy

Brain tumor irradiations were performed at the European Synchrotron Radiation Facility (ID17) as described previously (Serduc, Bouchet *et al.*, 2009). The X-ray spectrum extended from approximately 50 to 350 keV (median energy around 90 keV). The dose rate was ~16000 Gy s⁻¹. The beam was spatially fractionated into a 1 cm-wide array of microbeams by using a multi-slit collimator (Bräuer-Krisch, Requardt *et al.*, 2009). Two orthogonal arrays were used, each composed of 50 14 mm-high 50 μm-wide microbeams spaced 200 μm on-centre. The in-beam skin entrance dose was 480 Gy. Animal immobility during exposure was checked on three control video screens. The whole irradiation procedure lasted <2 min.

2.4. Dosimetry

The spatial configuration of the microbeams (width and spacing) was checked microscopically in radiochromic films (Gafchromic, HD-810) (Crosbie *et al.*, 2008) to ensure the correct alignment of the multi-slit collimator and thus the homogeneity of the dose distribution. No experimental dosimetry studies were performed. Monte Carlo dose computations, using a rat-head phantom (Siegbahn *et al.*, 2006) for this irradiation geometry, were carried out for a unique microbeam array (Fig. 1).

2.5. Survival analysis

The time between implantation and death was recorded as the survival time; one day was added in cases of euthanasia. Kaplan Meier survival data were plotted *versus* time after tumor implantation. The survival curves were compared using a log rank test in *Prism* (GraphPad Software, San Diego, USA).

2.6. Cytometry

Blood cells were counted in a Beckman apparatus in control (*n* = 6), JAI-51 (*n* = 5), MRT (*n* = 14) and MRT/JAI-51 (*n* = 7) treated animals. At D16 and D28 after implantation the brains were excised and cut at the tumor injection site by means of a pre-cooled Kopf matrix (David Kopf Instruments, USA). 1 mm³ tumor specimens were taken and used to make imprints on glass slides and air dried. DNA content was measured in 200 tumor cells per sample under a microscope (Zeiss, Germany) at the absorption maximum for the Feulgen stain, 546 nm, in areas chosen at random. Calibration was performed with human lymphocytes and normal glial cells as internal reference to define the normal diploid (2c) value. These measurements assess the DNA distribution pattern of the

tumor cell population. The ploidy of the 9L cell line which was used for injection was controlled by flow cytometry. The average DNA content in the G0/G1 phase of the 9LGS cell line was $\sim 3.5c$. The same data were found cytometrically on Feulgen-stained slides: the first peak in DNA content, corresponding to the G0/G1 phases, was between 3c and 4c, and for G2/M between 6.5 and 7.5c. Cells with DNA content between 4c and 6.5c were assigned to the S phase. Cells with DNA contents lower than those of G0/G1 cells displayed the morphology of apoptotic/necrotic cells. Cells with DNA contents $>7.5c$ were considered as cells that underwent endoreduplication. For each group, the mean \pm one standard deviation (SD) was calculated for the cell population in each phase and presented in Fig. 3. Statistical analyses were performed using the GraphPad Prism program; a two-way ANOVA test was used (Bonferroni post-tests). Values were considered significantly different when $p < 0.05$.

3. Results

3.1. Dosimetry

The dose profile for a single array of the microbeam is plotted in Fig. 1. The peak dose, deposited at a depth of 1 cm in rat brain, was 418 Gy, and generated a valley dose of 18.6 Gy (peak-to-valley dose ratio $\simeq 22.4$).

3.2. Survival

Fig. 2 shows that rats in the control and the JAI-51 group survived for a short time, 19 (± 1.5) and 18 (± 1.8) days after tumor inoculation, respectively. MRT significantly increased the median survival time (MST) of irradiated rats (186%, $p < 0.001$). When both treatments were applied, a significant increase in lifespan was found between the MRT (MST of 35.5 days) and MRT/JAI-51 groups [MST of 48 days after implantation, 252% ($p < 0.001$) and 135% ($p = 0.0367$) compared with the control and MRT groups, respectively].

3.3. Cytometry

Fig. 3 shows the repartition of the cells in the different phases of the cell cycle at D16 and D28. At D16 there was no difference in phase distribution between the control and JAI-




Figure 1
Calculated dose profile for a single microbeam array of a 10 mm \times 14 mm irradiation field. The peak-to-valley dose ratio calculated at a depth of 1 cm in a rat head is 22.4, resulting in a maximum valley dose of 18.6 Gy. The in-microbeam entrance dose was 480 Gy, delivering a 418 Gy peak dose at 1 cm depth.




Figure 2
Survival curves of rats bearing intracerebral 9LGS (grey), treated by JAI-51 (dashed black), irradiated by MRT (dashed grey) or treated by MRT and JAI-51 (solid black). MRT and/or JAI-51 were performed at day 14 after tumor implantation.

51 groups. MRT induced a significant arrest in the G2/M phase ($p < 0.001$) and a decrease in the G0/G1 population ($p < 0.01$). In the MRT/JAI-51 group, G2/M and G0/G1 populations were significantly higher and lower, respectively, than those found in the control group ($p < 0.001$). A significant difference was found in the G0/G1 population between MRT/JAI-51 and MRT groups (-20.5% , $p < 0.05$).

At D28, MRT irradiated tumors exhibited the same cell cycle profile as the unirradiated control group ($p > 0.05$ for each population). The G0/G1 cell population was found to be higher in the MRT group than in the MRT/JAI-51 group ($p < 0.05$). This may be due to the increases in the $<2.5c$ and $>8c$ population in the MRT/JAI-51 at D28. The hyperploidy values obtained for the different groups were compared with those of the control group. Only the hyperploidy in the MRT/JAI-51 at D28 was significantly higher than the control value ($p = 0.0007$).

3.4. Blood cell counts

The total blood cell counts carried out at D16 and D28 are shown in Table 1. None of the blood count values in the MRT/JAI-51 group showed significant differences from the control




Figure 3
Histograms showing the cycle distribution in control 9LGS, MRT and/or JAI-51 treated tumors at D16 and D28, i.e. two days and 14 days after treatment start. Each treatment started at day 14 after implantation. The different cell cycle phases, G0/G1, S, G2/M, endoreduplicative and apoptotic/necrotic cells are represented in light grey, dark grey, black, white and hashed histograms, respectively. *, **, ***: $p < 0.05$, 0.01, 0.001, significantly different from control (similar cell cycle stage). # $p < 0.05$.

Table 1

Number of red blood cells (RBC), white blood cells (WBC) and thrombocytes (\pm SD) counted in blood samples from rats having received either MRT, JAI-51 or both treatments.

Cell counts were performed 2 and 14 days after treatment starts (D16 and D28). The symbol (*) indicates significant difference from the control ($p = 0.02$). T l⁻¹ = trillion per litre.

Blood content	Day 16				Day 28	
	Control	JAI-52	MRT	MRT/JAI-52	MRT/JAI-52	MRT
WBC (g l ⁻¹)	3.3 (\pm 1.7)	5.9 (\pm 2.9)	2.2 (\pm 2.2)	2.3 (\pm 1.2)	7.0 (\pm 1)	9.0 (\pm 1)*
RBC (T l ⁻¹)	7.7 (\pm 1.5)	8.0 (\pm 0.5)	7.5 (\pm 0.7)	7.6 (\pm 1.1)	8.0 (\pm 1)	8.0 (\pm 0.2)
Thrombocytes (g l ⁻¹)	611 (\pm 202)	212 (\pm 174)*	568 (\pm 14)	488 (\pm 302)	716 (\pm 291)	868 (\pm 164)*

group. JAI-51 induced a significant decrease in thrombocyte number at D16 after treatment. The white blood cells count in the MRT group at D28 was significantly higher than that measured in the control group ($p = 0.02$).

4. Discussion

We have investigated the relevance of the association between a chalcone called JAI-51, inhibitor of tubulin polymerization, and MRT, on intracerebral 9LGS in rats. Our results showed that JAI-51 alone does not act on this tumor, but that it may be effective if a radiation treatment is given prior to its administration. Indeed, the MST of MRT-treated animals increased significantly when MRT was associated with JAI-51 treatment ($p = 0.0367$). The increase in lifespan was associated with a significant increase in the proportion of cells blocked in G2/M, as well as in proportions of endoreplicative (>8c peak) and pyknotic/apoptotic cells (sub-G0/G1 peak) two days after the start of the treatments.

All MRT studies performed on implanted brain tumors in rodents showed significant increases in lifespan of irradiated animals [*e.g.* 186% versus unirradiated controls, $p < 0.001$ (Laisue *et al.*, 1998; Serduc, Bouchet *et al.*, 2009; Serduc, Bräuer-Krisch *et al.*, 2009; Serduc *et al.*, 2008; Bouchet *et al.*, 2010)], in association with limited histological damage of irradiated normal brain tissues (for a review, see Bräuer-Krisch, Serduc *et al.*, 2009). However, some previous works revealed that a small percentage of brain tumor cells, ~2% according to Dilmanian *et al.* (2002), kept their proliferative activity after 'effective' MRT. More recent experiments confirmed this hypothesis: Ki67 positive tumor cells were found at the 9LGS margins after MRT (Bouchet *et al.*, 2010; Serduc, Bouchet *et al.*, 2009; Serduc, Bräuer-Krisch *et al.*, 2009; Serduc *et al.*, 2008). Here we show for the first time that the tubulin polymerization inhibitor JAI-51 used as adjuvant helps in tumor control after MRT. Conversely, JAI-51 alone had a significant effect on subcutaneously implanted GL26 tumor cells in mice by slowing tumor growth (Boumendjel *et al.*, 2009), but the tumor micro-environments were drastically different between the two models studied. In the GL26 glioma, tumoral blood vessels were fenestrated, while the 9LGS exhibited a weakly disrupted blood-tumor barrier (Bouchet *et al.*, 2010; Lemasson *et al.*, 2010). This factor might have considerably limited the diffusion of the chemo-agent (349 Da) from the blood into the tumor parenchyma; diffusion of JAI-51 into 9LGS probably remained insufficient to have a

significant effect on tumor growth and survival. Thus, a major obstacle to the efficiency of chemotherapy for brain tumors may reside in the presence of the blood-brain (and blood-tumor) barrier(s) which limit considerably the diffusion of these molecules into the tumor (van Vulpen *et al.*, 2002). We recently demonstrated that similar MRT protocols (400 Gy, 50/200 μ m), applied to 9LGS, specifically increased tumor vessel permeability (Bouchet *et al.*, 2010). Our present results confirm that a pre-irradiation of intracerebral 9LGS is required to allow an uptake of JAI-51 that is capable of exerting a significant adjuvant effect.

The increase in MST of rats which received both treatments is therefore likely to be due to the synergistic effect of MRT with JAI-51. It has been shown *in vivo* that MRT protocols similar to that used in our study induced an increase in tumor blood vessel permeability while no changes were observed in normal brain tissue (Bouchet *et al.*, 2010; Dilmanian *et al.*, 2003; Serduc *et al.*, 2008). The radiation-induced increase in the blood-tumor barrier might thus have allowed a preferential uptake of JAI-51 by the tumor. This hypothesis would be in keeping with the significant difference between the MRT and MRT/JAI-51 groups, in proportions of G0/G1 cells observed on D16. Indeed, MRT induced a significant redistribution of the cell cycle stages of tumor cells: a decreased proportion of tumor cells in the G0/G1 stages (-20% , $p < 0.05$, compared with the MRT group), as well as a blockade of cells in G2/M as detected by a slight but non-significant increase of the proportion of G2/M and <2c cells. The longer blockade in G2/M and the accumulation of <2c and >8c tumor cells slowed tumor growth and explained, at least in part, the prolonged survival obtained in the MRT/JAI-51 group. The biological mechanisms of cell death induced by JAI-51, described elsewhere (Boumendjel *et al.*, 2008, 2009), correlate with the results of our cell cycle study. At D28, the results of cell cycle analysis in the MRT group were similar to those noted in the control group, an indication that the tumor cells that have survived after the irradiation were able to proliferate after a short blockade in G2/M. Cancer cells may use endoreduplication as means of survival during mitotic inhibition; for instance, some mutant cancer cells undergo endoreduplication rather than apoptosis upon treatment with anti-mitotic drugs such as colcemid and vinblastine (Lee *et al.*, 2009). However, some of these polyploid cancer cells can revert to the mitotic cell cycle by means of a process of genome reduction, 'depolyplodization'. Survival from anti-mitotic drug effects by endoreduplication and depolyplodi-

zation may be the strategy of cancer cells aiming to become less sensitive to anti-mitotic drugs (Lee *et al.*, 2009).

In this study we applied the JAI-51 regimen that has been used previously for the human glioblastoma cell line (GL26) implanted in mouse legs (Boumendjel *et al.*, 2009). The MST of the MRT/JAI-51 group might be increased by optimizing drug delivery, especially by the delay between the first injection and MRT, a parameter that might be refined by varying the timing of the first drug injection. Khil *et al.* (2000) showed that the optimal choice of the time schedule for BCNU adjuvant chemotherapy of the 9LGS tumor was directly linked to significant improvement of the animal survival. Furthermore, the basic geometry chosen for tumor targeting in this study could be improved by use of recent improvements developed at the ESRF. Three-dimensional interlaced or interspersed geometry (Serduc, Bräuer-Krisch *et al.*, 2009; Serduc, Bräuer-Krisch *et al.*, 2010; Bräuer-Krisch *et al.*, 2005) combined with image-guided irradiation (Serduc, Berruyer *et al.*, 2010) may improve MRT efficiency, mainly by reducing the radiation-induced normal brain tissue damage while delivering a high (uniform) dose to the tumor.

To conclude, we report here for the first time the potential of a chalcone chemotherapy associated with MRT. The adjunction of an antimetabolic drug at an optimal time after MRT might help in reducing the radiation dose to achieve an even better sparing of normal tissues.

Enam Khalil contributed to this work during her sabbatical leave which was financially supported by the University of Jordan, Amman, Jordan.

References

- Bauman, G. S., MacDonald, W., Moore, E., Ramsey, D. A., Fisher, B. J., Amberger, V. R. & Del Maestro, R. M. (1999). *J. Neurooncol.* **44**, 223–231.
- Bouchet, A., Lemasson, B., Leduc, G., Maisin, C., Bräuer-Krisch, E., Siegbahn, E. A., Renaud, L., Remy, C., Bravin, A., Laissue, J. A., Barbier, E. & Serduc, R. (2010). *Int. J. Radiat. Oncol. Biol. Phys.* **78**, 1503–1512.
- Boumendjel, A., Boccard, J., Carrupt, P. A., Nicolle, E., Blanc, M., Geze, A., Choisnard, L., Wouessidjewe, D., Matera, E. L. & Dumontet, C. (2008). *J. Med. Chem.* **51**, 2307–2310.
- Boumendjel, A., McLeer-Florin, A., Champelovier, P., Allegro, D., Muhammad, D., Souard, F., Derouazi, M., Peyrot, V., Toussaint, B. & Boutonnat, J. (2009). *BMC Cancer*, **9**, 242.
- Bräuer-Krisch, E., Requardt, H., Brochard, T., Berruyer, G., Renier, M., Laissue, J. A. & Bravin, A. (2009). *Rev. Sci. Instrum.* **80**, 074301.
- Bräuer-Krisch, E., Requardt, H., Regnard, P., Corde, S., Siegbahn, E. A., Leduc, G., Blattmann, H., Laissue, J. & Bravin, A. (2005). *Nucl. Instrum. Methods Phys. Res. A*, **548**, 69–71.
- Bräuer-Krisch, E., Serduc, R., Siegbahn, E. A., Le Duc, G., Prezado, Y., Bravin, A., Blattmann, H. & Laissue, J. A. (2009). *Mutat. Res.* **704**, 160–166.
- Crosbie, J. C., Svalbe, I., Midgley, S. M., Yagi, N., Rogers, P. A. & Lewis, R. A. (2008). *Phys. Med. Biol.* **53**, 6861–6877.
- Dilmanian, F. A., Button, T. M., Le Duc, G., Zhong, N., Peña, L. A., Smith, J. A., Martinez, S. R., Bacarian, T., Tammam, J., Ren, B., Farmer, P. M., Kalef-Ezra, J., Micca, P. L., Nawrocky, M. M., Niederer, J. A., Recksiek, F. P., Fuchs, A. & Rosen, E. M. (2002). *Neuro-oncol.* **4**, 26–38.
- Dilmanian, F. A., Hainfeld, J. F., Kruse, C. A., Cool, C. D., Sze, C. I., Laterra, J. S., Feldman, A., Gatley, S. J., Nawrocky, M. M. & Yakupov, R. (2003). *NSLS Activity Report 2002*, Abstract dilm0599, <http://www.bnl.gov/isd/documents/25005/Abstracts/dilm0599.pdf>.
- Duraj, J., Zazrivcova, K., Bodo, J., Sulikova, M. & Sedlak, J. (2005). *Neoplasma*, **52**, 273–279.
- Jeong, J. M., Choi, C. H., Kang, S. K., Lee, I. H., Lee, J. Y. & Jung, H. (2007). *J. Pharm. Pharm. Sci.* **10**, 537–546.
- Khil, M. S., Kolozsvary, A., Apple, M. & Kim, J. H. (2000). *Int. J. Radiat. Oncol. Biol. Phys.* **47**, 511–516.
- Kim, J. H., Khil, M. S., Kolozsvary, A., Gutierrez, J. A. & Brown, S. L. (1999). *Int. J. Radiat. Oncol. Biol. Phys.* **45**, 1035–1040.
- Laissue, J. A., Geiser, G., Spanne, P. O., Dilmanian, F. A., Gebbers, J. O., Geiser, M., Wu, X. Y., Makar, M. S., Micca, P. L., Nawrocky, M. M., Joel, D. D. & Slatkin, D. N. (1998). *Int. J. Cancer*, **78**, 654–660.
- Lee, H. O., Davidson, J. M. & Duronio, R. J. (2009). *Genes Dev.* **23**, 2461–2477.
- Lemasson, B., Serduc, R., Maisin, C., Bouchet, A., Coquery, N., Robert, P., Le Duc, G., Troprès, I., Rémy, C. & Barbier, E. L. (2010). *Radiology*, **257**, 342–352.
- Nakagawa-Goto, K., Chang, P. C., Lai, C. Y., Hung, H. Y., Chen, T. H., Wu, P. C., Zhu, H., Sedykh, A., Bastow, K. F. & Lee, K. H. (2010). *J. Med. Chem.* **53**, 6699–6705.
- Serduc, R., Berruyer, G., Brochard, T., Renier, M. & Nemoz, C. (2010). *J. Synchrotron Rad.* **17**, 325–331.
- Serduc, R., Bouchet, A., Bräuer-Krisch, E., Laissue, J. A., Spiga, J., Sarun, S., Bravin, A., Fonta, C., Renaud, L., Boutonnat, J., Siegbahn, E. A., Estève, F. & Le Duc, G. (2009). *Phys. Med. Biol.* **54**, 6711–6724.
- Serduc, R., Bräuer-Krisch, E., Bouchet, A., Renaud, L., Brochard, T., Bravin, A., Laissue, J. & Le Duc, G. (2009). *J. Synchrotron Rad.* **16**, 587–590.
- Serduc, R., Bräuer-Krisch, E., Siegbahn, E. A., Bouchet, A., Pouyatos, B., Carron, R., Pannetier, N., Renaud, L., Berruyer, G., Nemoz, C., Brochard, T., Remy, C., Barbier, E. L., Bravin, A., Le Duc, G., Depaulis, A., Esteve, F. & Laissue, J. A. (2010). *PLoS One*, **5**, e9028.
- Serduc, R., Christen, T., Laissue, J., Farion, R., Bouchet, A., Sanden, B., Segebarth, C., Bräuer-Krisch, E., Le Duc, G., Bravin, A., Rémy, C. & Barbier, E. L. (2008). *Phys. Med. Biol.* **53**, 3609–3622.
- Siegbahn, E. A., Stepanek, J., Bräuer-Krisch, E. & Bravin, A. (2006). *Med. Phys.* **33**, 3248–3259.
- Slatkin, D. N., Dilmanian, F. A. & Spanne, P. (1994). US Patent 5339347.
- Slatkin, D. N., Spanne, P., Dilmanian, F. A., Gebbers, J. O. & Laissue, J. A. (1995). *Proc. Natl Acad. Sci. USA*, **92**, 8783–8787.
- Slatkin, D. N., Spanne, P., Dilmanian, F. A. & Sandborg, M. (1992). *Med. Phys.* **19**, 1395–1400.
- Smilowitz, H. M., Blattmann, H., Bräuer-Krisch, E., Bravin, A., Di Michiel, M., Gebbers, J. O., Hanson, A. L., Lyubimova, N., Slatkin, D. N., Stepanek, J. & Laissue, J. A. (2006). *J. Neurooncol.* **78**, 135–143.
- Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, R., Lacombe, D., Cairncross, J. G., Eisenhauer, E. & Mirimanoff, R. O. (2005). *N. Engl. J. Med.* **352**, 987–996.
- Stupp, R. & Roila, F. (2008). *Ann. Oncol.* **19**(Suppl. 2), ii83–ii85.
- Vredenburgh, J. J., Desjardins, A., Herndon, J. E. II, Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., Bigner, D. D., Friedman, A. H. & Friedman, H. S. (2007). *Clin. Cancer Res.* **13**, 1253–1259.
- Vredenburgh, J. J., Desjardins, A., Herndon, J. E. II, Marcelllo, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., Wagner, M., Bailey, L., Bigner, D. D., Friedman, A. H. & Friedman, H. S. (2007). *J. Clin. Oncol.* **25**, 4722–4729.
- Vulpen, M. van, Kal, H. B., Taphoorn, M. J. & El-Sharouni, S. Y. (2002). *Oncol. Rep.* **9**, 683–688.